Can an adult with autosomal dominant polycystic kidney disease and mild‑to‑moderate chronic kidney disease use cannabinoids to treat fatigue, and what dosing regimen is recommended?

Cannabinoids for ADPKD-Related Fatigue

Cannabinoids should not be used to treat fatigue in adults with ADPKD and mild-to-moderate CKD, as there is no evidence supporting their efficacy for this indication, and the 2025 KDIGO ADPKD guideline explicitly advises counseling patients about the potential dangers of cannabis products, particularly the risk of acute kidney injury from product contamination and synthetic versions. 1

Guideline-Based Recommendation

The most recent and authoritative guidance comes from the 2025 KDIGO ADPKD Clinical Practice Guideline, which addresses cannabis use directly in the lifestyle management section:

• All people with ADPKD should receive counseling about cannabis products, with specific warnings about the potential dangers of acute kidney injury related to product contamination and synthetic versions. 1
• This represents a cautionary stance rather than a therapeutic recommendation, emphasizing safety concerns over potential benefits. 1

Evidence Gap for Fatigue Management

No clinical evidence exists supporting cannabinoid use specifically for fatigue in ADPKD patients:

• The 2024 ASCO guideline on cannabis in cancer patients found no statistically significant differences in quality of life or specific symptoms (including fatigue) when comparing nabilone to placebo in a 7-week randomized controlled trial. 1
• A 2022 narrative review on cannabinoids for symptom management in kidney failure identified potential roles for pruritus, nausea, insomnia, chronic neuropathic pain, anorexia, and restless legs syndrome—but fatigue was not among the symptoms with supporting evidence. 2
• Survey data from 2023 showed that while 50% of kidney disease patients would consider trying cannabis for various symptoms, the most common actual uses were for pain (39.4%), sleep (35.0%), and recreation (52.5%)—not fatigue. 3

Safety Concerns in CKD Population

Multiple kidney-specific risks make cannabinoid use particularly problematic in ADPKD with CKD:

• Acute kidney injury risk: Product contamination and synthetic cannabinoid versions pose documented nephrotoxic risks. 1
• Renal function monitoring: Cannabis does not appear to affect kidney function in healthy individuals, but renal function should be closely monitored in those with CKD, and the lowest effective dose should be used if prescribed for other indications. 4
• Drug interactions: Cannabidiol (CBD) can raise tacrolimus levels, which is relevant for post-transplant ADPKD patients. 4
• Unregulated products: Consumers have easy access to unregulated CBD products with inaccurate labeling and false health claims. 4

Alternative Approaches to Fatigue in ADPKD

Rather than cannabinoids, evidence-based lifestyle interventions should be prioritized:

• Physical activity: Adults with ADPKD should undertake moderate-intensity physical activity for at least 150 minutes per week or to a level compatible with their cardiovascular and physical tolerance, plus strength training at least 2 sessions per week. 1
• Nutritional counseling: Work with accredited nutrition providers or registered dietitians for individualized counseling, particularly for those with CKD G4-G5, overweight/obesity, or malnutrition/sarcopenia. 1
• Psychosocial screening: Healthcare providers should screen for and conduct periodic assessment of psychosocial issues, as key stressors related to ADPKD (physical, social, family-related, and inheritance-related) can contribute to fatigue. 1

If Cannabinoids Were Considered Despite Lack of Evidence

Should a clinician still consider cannabinoids after exhausting evidence-based options, the following dosing principles from cancer literature would apply (though not validated in ADPKD):

• Start low, go slow approach: Begin with the lowest possible dose and titrate gradually while balancing potential risks and benefits. 1
• Oral THC (dronabinol): May be started at 2.5 mg three times daily and up-titrated to 10 mg three to four times daily. 1
• Oral nabilone: May be initiated at 1 mg twice daily and up-titrated to a maximum of 2 mg four times daily. 1
• No renal dose adjustment required: However, adverse effects and drug interactions can be significant dose-limiting barriers. 1
• Common side effects: Euphoria, drowsiness, dizziness, vertigo, hallucinations, sedation, disorientation, and mood changes. 1
• Timing considerations: Oral THC onset is 30 minutes to 2 hours, lasting 5-8 hours; patients must be cautioned about delayed onset and avoid stacking doses. 1
• Food interactions: Administration with high-fat meals significantly increases oral cannabinoid absorption and may exacerbate side effects. 1

Common Pitfalls to Avoid

• Do not prescribe cannabinoids for fatigue in ADPKD based on anecdotal reports or patient requests without acknowledging the complete absence of supporting evidence. 2
• Do not assume cannabis is "natural and safe" in the CKD population—contamination and synthetic versions pose real nephrotoxic risks. 1
• Do not overlook evidence-based interventions (physical activity, nutrition, psychosocial support) that have documented benefits for ADPKD patients. 1
• Do not fail to document cannabis use if patients are using it—only 33.8% of cannabis users in one survey believed their physicians were aware of their use. 3